What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel

L. Testa, R. Bhindi, W. J. Van Gaal, R. A. Latini, S. Pizzocri, S. Lanotte, G. G L Biondi Zoccai, M. Valgimigli, M. L. Laudisa, N. Brambilla, A. P. Banning, F. Bedogni

Research output: Contribution to journalArticle

Abstract

Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.

Original languageEnglish
Pages (from-to)367-377
Number of pages11
JournalQJM
Volume103
Issue number6
DOIs
Publication statusPublished - Jun 6 2010

Fingerprint

clopidogrel
Blood Platelets
Thienopyridines
Ticlopidine
Drug Delivery Systems
Adenosine Diphosphate
Clinical Trials
Hemorrhage
Prasugrel Hydrochloride

ASJC Scopus subject areas

  • Medicine(all)

Cite this

What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. / Testa, L.; Bhindi, R.; Van Gaal, W. J.; Latini, R. A.; Pizzocri, S.; Lanotte, S.; Biondi Zoccai, G. G L; Valgimigli, M.; Laudisa, M. L.; Brambilla, N.; Banning, A. P.; Bedogni, F.

In: QJM, Vol. 103, No. 6, 06.06.2010, p. 367-377.

Research output: Contribution to journalArticle

Testa, L, Bhindi, R, Van Gaal, WJ, Latini, RA, Pizzocri, S, Lanotte, S, Biondi Zoccai, GGL, Valgimigli, M, Laudisa, ML, Brambilla, N, Banning, AP & Bedogni, F 2010, 'What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel', QJM, vol. 103, no. 6, pp. 367-377. https://doi.org/10.1093/qjmed/hcq017
Testa, L. ; Bhindi, R. ; Van Gaal, W. J. ; Latini, R. A. ; Pizzocri, S. ; Lanotte, S. ; Biondi Zoccai, G. G L ; Valgimigli, M. ; Laudisa, M. L. ; Brambilla, N. ; Banning, A. P. ; Bedogni, F. / What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. In: QJM. 2010 ; Vol. 103, No. 6. pp. 367-377.
@article{1dc1e04eee4f472abdb03f4a603a1388,
title = "What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel",
abstract = "Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.",
author = "L. Testa and R. Bhindi and {Van Gaal}, {W. J.} and Latini, {R. A.} and S. Pizzocri and S. Lanotte and {Biondi Zoccai}, {G. G L} and M. Valgimigli and Laudisa, {M. L.} and N. Brambilla and Banning, {A. P.} and F. Bedogni",
year = "2010",
month = "6",
day = "6",
doi = "10.1093/qjmed/hcq017",
language = "English",
volume = "103",
pages = "367--377",
journal = "QJM - Monthly Journal of the Association of Physicians",
issn = "1460-2725",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel

AU - Testa, L.

AU - Bhindi, R.

AU - Van Gaal, W. J.

AU - Latini, R. A.

AU - Pizzocri, S.

AU - Lanotte, S.

AU - Biondi Zoccai, G. G L

AU - Valgimigli, M.

AU - Laudisa, M. L.

AU - Brambilla, N.

AU - Banning, A. P.

AU - Bedogni, F.

PY - 2010/6/6

Y1 - 2010/6/6

N2 - Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.

AB - Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.

UR - http://www.scopus.com/inward/record.url?scp=79951993940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951993940&partnerID=8YFLogxK

U2 - 10.1093/qjmed/hcq017

DO - 10.1093/qjmed/hcq017

M3 - Article

C2 - 20211848

AN - SCOPUS:79951993940

VL - 103

SP - 367

EP - 377

JO - QJM - Monthly Journal of the Association of Physicians

JF - QJM - Monthly Journal of the Association of Physicians

SN - 1460-2725

IS - 6

ER -